The Library
Cabazitaxel in platinum pre-treated patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression after platinum based chemotherapy : results of the phase II CAB-B1 trial
Tools
Tools
Tools
Zarkar, A., Marshall, Andrea, Davies, A., Ford, D., James, N. D. and Dunn, Janet A. (2019) Cabazitaxel in platinum pre-treated patients with locally advanced or metastatic transitional cell carcinoma who developed disease progression after platinum based chemotherapy : results of the phase II CAB-B1 trial. International Journal of Cancer Research & Therapy, 4 (4). ISSN 2476-2377.
|
PDF
WRAP-cabazitaxel-in-platinum-pre-treated-patients-with-locally-advanced-or-metastatic-transitional-cell-carcinoma-Dunn-2019.pdf - Published Version - Requires a PDF viewer. Available under License Creative Commons Attribution 4.0. Download (354Kb) | Preview |
Official URL: https://www.opastonline.com/international-journal-...
Abstract
There is a paucity of chemotherapy options for patients with urothelial cancers who have relapsed following platinum based chemotherapy (CT).
CAB-B1 was a single centre phase II randomised controlled trial of Cabazitaxel (CAB; 25mg/m2 q3 week for 6 cycles) versus
best supportive care (BSC) in patients with histologically proven transitional cell carcinoma (TCC), locally advanced or
metastatic, who had recurred after receiving platinum based treatment. Primary outcome was overall response rate (ORR)
using RESIST. Secondary outcomes included Progression Free Survival (PFS) and Overall Survival (OS).
Between January 2013 and October 2016, 20 patients were randomised (10 on each arm). BSC included paclitaxel CT for 9
patients and radiotherapy for 1 patient. 8 patients completed 6 cycles of CT (3 on CAB; 5 on BSC). 2 patients had an ORR
on CAB and 1 patient on BSC. Median OS was 5.8 months (95% confidence interval (CI) 0.7-14.6) for CAB patients and
7.5 months (95% CI 1.0-10.8) for BSC patients. Median PFS was 4.8 months (95% CI 0.7-8.3) for CAB patients and 3.7
months (95% CI 1.0-7.0) for BSC patients.
CAB-B1 successfully reached the efficacy target for 1st stage, showing that there could be a role for CAB in these patients.
| Item Type: | Journal Article | ||||||
|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology |
||||||
| Divisions: | Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Clinical Trials Unit Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School > Health Sciences Faculty of Science, Engineering and Medicine > Medicine > Warwick Medical School |
||||||
| Library of Congress Subject Headings (LCSH): | Bladder -- Cancer, Bladder -- Cancer -- Treatment, Cancer -- Chemotherapy | ||||||
| Journal or Publication Title: | International Journal of Cancer Research & Therapy | ||||||
| Publisher: | Opast Publishing Group | ||||||
| ISSN: | 2476-2377 | ||||||
| Official Date: | 5 November 2019 | ||||||
| Dates: |
|
||||||
| Volume: | 4 | ||||||
| Number: | 4 | ||||||
| Status: | Peer Reviewed | ||||||
| Publication Status: | Published | ||||||
| Access rights to Published version: | Open Access (Creative Commons) | ||||||
| Date of first compliant deposit: | 4 December 2019 | ||||||
| Date of first compliant Open Access: | 9 December 2019 | ||||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
